Download PDF
Semin Reprod Med 2015; 33(05): 341-349
DOI: 10.1055/s-0035-1563407
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Endometrial Cancer Stem Cell as a Potential Therapeutic Target

Satoru Kyo
1   Department of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Shimane, Japan
,
Kiyoko Kato
2   Department of Obstetrics and Gynecology, Kyushu University, Higashi-ku, Fukuoka, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
18 August 2015 (online)

    Permissions and Reprints

Abstract

Adult stem cells have recently been identified in several types of mature tissue and it has been also suggested that stem-like cells exist in cancerous tissues. It is believed that many cancer stem cells (CSCs) upregulate the expression of drug transporters, allowing them to efficiently pump antitumor agents out of the cells. CSCs reside in a quiescent state, making them resistant to chemotherapeutic agents that target rapidly cycling cells. They are also endowed with a more invasive and metastatic phenotype. These results indicate the requirement to develop a new target treatment for CSCs. There are several methods for the identification of CSCs; for example, detection by CSC markers, such as CD133, CD44, CD117(c-kit), aldehyde dehydrogenase 1 (ALDH1), and isolation of side population (SP), which are identified based on their ability to remove intracellular Hoechst 33342, a fluorescent dye. Here, we review recent articles that show the presence of stem cells in endometrial cancer and introduce the results of our own recent studies using CD133 or CD117 positive cells and SP cells.

Keywords

endometrium - stem cells - endometrial cancer - therapeutic target
 

  • References

  • 1 Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8 (10) 755-768
    CrossrefPubMedGoogle Scholar
  • 2 Lapidot T, Sirard C, Vormoor J , et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367 (6464) 645-648
    CrossrefPubMedGoogle Scholar
  • 3 Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3 (7) 730-737
    CrossrefPubMedGoogle Scholar
  • 4 Bao S, Wu Q, McLendon RE , et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444 (7120) 756-760
    CrossrefPubMedGoogle Scholar
  • 5 Prince ME, Sivanandan R, Kaczorowski A , et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104 (3) 973-978
    CrossrefPubMedGoogle Scholar
  • 6 Ginestier C, Hur MH, Charafe-Jauffret E , et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1 (5) 555-567
    CrossrefPubMedGoogle Scholar
  • 7 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100 (7) 3983-3988
    CrossrefPubMedGoogle Scholar
  • 8 Eramo A, Lotti F, Sette G , et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15 (3) 504-514
    CrossrefPubMedGoogle Scholar
  • 9 Jiang F, Qiu Q, Khanna A , et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7 (3) 330-338
    CrossrefPubMedGoogle Scholar
  • 10 Ding W, Mouzaki M, You H , et al. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 2009; 49 (4) 1277-1286
    CrossrefPubMedGoogle Scholar
  • 11 Yang ZF, Ho DW, Ng MN , et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13 (2) 153-166
    CrossrefPubMedGoogle Scholar
  • 12 Takaishi S, Okumura T, Tu S , et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27 (5) 1006-1020
    CrossrefPubMedGoogle Scholar
  • 13 Li C, Heidt DG, Dalerba P , et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67 (3) 1030-1037
    CrossrefPubMedGoogle Scholar
  • 14 Hermann PC, Huber SL, Herrler T , et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1 (3) 313-323
    CrossrefPubMedGoogle Scholar
  • 15 O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445 (7123) 106-110
    CrossrefPubMedGoogle Scholar
  • 16 Ricci-Vitiani L, Lombardi DG, Pilozzi E , et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445 (7123) 111-115
    CrossrefPubMedGoogle Scholar
  • 17 Nakamura M, Kyo S, Zhang B , et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol 2010; 41 (11) 1516-1529
    CrossrefPubMedGoogle Scholar
  • 18 Rutella S, Bonanno G, Procoli A , et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 2009; 15 (13) 4299-4311
    CrossrefPubMedGoogle Scholar
  • 19 Kato K, Takao T, Kuboyama A , et al. Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. Am J Pathol 2010; 176 (1) 381-392
    CrossrefPubMedGoogle Scholar
  • 20 Zhang X, Kyo S, Nakamura M , et al. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells. Cancer Lett 2014; 345 (1) 106-114
    CrossrefPubMedGoogle Scholar
  • 21 Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A 2011; 108 (16) 6468-6473
    CrossrefPubMedGoogle Scholar
  • 22 Silva IA, Bai S, McLean K , et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71 (11) 3991-4001
    CrossrefPubMedGoogle Scholar
  • 23 Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008; 68 (23) 9703-9711
    CrossrefPubMedGoogle Scholar
  • 24 Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65 (23) 10946-10951
    CrossrefPubMedGoogle Scholar
  • 25 Jaksch M, Múnera J, Bajpai R, Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008; 68 (19) 7882-7886
    CrossrefPubMedGoogle Scholar
  • 26 Schatton T, Murphy GF, Frank NY , et al. Identification of cells initiating human melanomas. Nature 2008; 451 (7176) 345-349
    CrossrefPubMedGoogle Scholar
  • 27 Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res 2009; 69 (21) 8241-8248
    CrossrefPubMedGoogle Scholar
  • 28 Kyo S, Maida Y, Inoue M. Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions. Cancer Lett 2011; 308 (2) 123-133
    CrossrefPubMedGoogle Scholar
  • 29 Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006; 23 (2) 91-102
    CrossrefPubMedGoogle Scholar
  • 30 McIntyre A, Summersgill B, Grygalewicz B , et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005; 65 (18) 8085-8089
    CrossrefPubMedGoogle Scholar
  • 31 Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005; 46 (2) 247-255
    CrossrefPubMedGoogle Scholar
  • 32 Edling CE, Hallberg B. c-Kit—a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 2007; 39 (11) 1995-1998
    CrossrefPubMedGoogle Scholar
  • 33 Levina V, Marrangoni A, Wang T , et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 2010; 70 (1) 338-346
    PubMedGoogle Scholar
  • 34 Zhang S, Balch C, Chan MW , et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68 (11) 4311-4320
    CrossrefPubMedGoogle Scholar
  • 35 Kim M, Turnquist H, Jackson J , et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002; 8 (1) 22-28
    PubMedGoogle Scholar
  • 36 Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22 (47) 7340-7358
    CrossrefPubMedGoogle Scholar
  • 37 Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors?. Cancer Treat Rev 2009; 35 (5) 403-408
    CrossrefPubMedGoogle Scholar
  • 38 Zhang M, Song T, Yang L , et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 2008; 27: 85
    CrossrefPubMedGoogle Scholar
  • 39 Horst D, Scheel SK, Liebmann S , et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009; 219 (4) 427-434
    CrossrefPubMedGoogle Scholar
  • 40 Maeda S, Shinchi H, Kurahara H , et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98 (8) 1389-1397
    CrossrefPubMedGoogle Scholar
  • 41 Chen YC, Chen YW, Hsu HS , et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009; 385 (3) 307-313
    CrossrefPubMedGoogle Scholar
  • 42 Rasheed ZA, Yang J, Wang Q , et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010; 102 (5) 340-351
    CrossrefPubMedGoogle Scholar
  • 43 Li T, Su Y, Mei Y , et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010; 90 (2) 234-244
    CrossrefPubMedGoogle Scholar
  • 44 Ran D, Schubert M, Pietsch L , et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009; 37 (12) 1423-1434
    CrossrefPubMedGoogle Scholar
  • 45 Cheung AM, Wan TS, Leung JC , et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007; 21 (7) 1423-1430
    CrossrefPubMedGoogle Scholar
  • 46 Charafe-Jauffret E, Ginestier C, Iovino F , et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16 (1) 45-55
    CrossrefPubMedGoogle Scholar
  • 47 Tanei T, Morimoto K, Shimazu K , et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009; 15 (12) 4234-4241
    CrossrefPubMedGoogle Scholar
  • 48 Morimoto K, Kim SJ, Tanei T , et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009; 100 (6) 1062-1068
    CrossrefPubMedGoogle Scholar
  • 49 Nakamura M, Zhang X, Mizumoto Y , et al. Molecular characterization of CD133+ cancer stem-like cells in endometrial cancer. Int J Oncol 2014; 44 (3) 669-677
    PubMedGoogle Scholar
  • 50 Gelmini S, Mangoni M, Serio M, Romagnani P, Lazzeri E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J Endocrinol Invest 2008; 31 (9) 809-819
    CrossrefPubMedGoogle Scholar
  • 51 Gelmini S, Mangoni M, Castiglione F , et al. The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis 2009; 26 (3) 261-268
    CrossrefPubMedGoogle Scholar
  • 52 Krohn A, Song YH, Muehlberg F, Droll L, Beckmann C, Alt E. CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Cancer Lett 2009; 280 (1) 65-71
    CrossrefPubMedGoogle Scholar
  • 53 Kyo S. Endometrial cancer stem cells: are they a possible therapeutic target?. Curr Obstet Gynecol Rep 2013; 2: 1-10
    CrossrefPubMedGoogle Scholar
  • 54 Phesse TJ, Clarke AR. Normal stem cells in cancer prone epithelial tissues. Br J Cancer 2009; 100 (2) 221-227
    CrossrefPubMedGoogle Scholar
  • 55 Mutter GL, Lin MC, Fitzgerald JT , et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92 (11) 924-930
    CrossrefPubMedGoogle Scholar
  • 56 Barker N, Ridgway RA, van Es JH , et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457 (7229) 608-611
    CrossrefPubMedGoogle Scholar
  • 57 Mizumoto Y, Kyo S, Ohno S , et al. Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements. Oncogene 2006; 25 (41) 5673-5682
    CrossrefPubMedGoogle Scholar
  • 58 Grunewald M, Avraham I, Dor Y , et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124 (1) 175-189
    CrossrefPubMedGoogle Scholar
  • 59 Orimo A, Gupta PB, Sgroi DC , et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121 (3) 335-348
    CrossrefPubMedGoogle Scholar
  • 60 Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432 (7015) 332-337
    CrossrefPubMedGoogle Scholar
  • 61 Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 2003; 63 (12) 3386-3394
    PubMedGoogle Scholar
  • 62 Mani SA, Guo W, Liao MJ , et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133 (4) 704-715
    CrossrefPubMedGoogle Scholar
  • 63 Kusunoki S, Kato K, Tabu K , et al. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol 2013; 129 (3) 598-605
    CrossrefPubMedGoogle Scholar
  • 64 Sil H, Sen T, Chatterjee A. Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. Oncol Res 2011; 19 (7) 335-348
    CrossrefPubMedGoogle Scholar
  • 65 Thomas F, Holly JM, Persad R, Bahl A, Perks CM. Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate 2010; 70 (8) 856-865
    PubMedGoogle Scholar
  • 66 Pontiggia O, Sampayo R, Raffo D , et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res Treat 2012; 133 (2) 459-471
    CrossrefPubMedGoogle Scholar
  • 67 De Toni-Costes F, Despeaux M, Bertrand J , et al. A New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells. PLoS ONE 2010; 5 (3) e9807
    CrossrefPubMedGoogle Scholar
  • 68 Amundson SA, Smilenov LB. Integration of biological knowledge and gene expression data for biomarker selection: FN1 as a potential predictor of radiation resistance in head and neck cancer. Cancer Biol Ther 2010; 10 (12) 1252-1255
    CrossrefPubMedGoogle Scholar
  • 69 Yusuf N, Inagaki T, Kusunoki S , et al. SPARC was overexpressed in human endometrial cancer stem-like cells and promoted migration activity. Gynecol Oncol 2014; 134 (2) 356-363
    CrossrefPubMedGoogle Scholar
  • 70 Hovinga KE, Shimizu F, Wang R , et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010; 28 (6) 1019-1029
    CrossrefPubMedGoogle Scholar
  • 71 Garzia L, Andolfo I, Cusanelli E , et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 2009; 4 (3) e4998
    CrossrefPubMedGoogle Scholar
  • 72 Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012; 13 (2) e83-e89
    CrossrefPubMedGoogle Scholar
  • 73 Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107 (4) 600-608
    CrossrefPubMedGoogle Scholar
  • 74 Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5 (10) 981-989
    CrossrefPubMedGoogle Scholar
  • 75 Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26 (37) 5420-5432
    CrossrefPubMedGoogle Scholar
  • 76 Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26 (37) 5541-5552
    CrossrefPubMedGoogle Scholar
  • 77 Blackwell L, Norris J, Suto CM, Janzen WP. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci 2008; 82 (21-22) 1050-1058
    CrossrefPubMedGoogle Scholar
  • 78 Takai N, Desmond JC, Kumagai T , et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10 (3) 1141-1149
    CrossrefPubMedGoogle Scholar
  • 79 Jiang S, Dowdy SC, Meng XW , et al. Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells. Gynecol Oncol 2007; 105 (2) 493-500
    CrossrefPubMedGoogle Scholar
  • 80 Ahn MY, Jung JH, Na YJ, Kim HS. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008; 108 (1) 27-33
    CrossrefPubMedGoogle Scholar
  • 81 Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot (Tokyo) 1990; 43 (9) 1101-1106
    CrossrefPubMedGoogle Scholar
  • 82 Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265 (28) 17174-17179
    PubMedGoogle Scholar
  • 83 Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004; 101 (12) 2760-2770
    CrossrefPubMedGoogle Scholar
  • 84 Terao Y, Nishida J, Horiuchi S , et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer 2001; 94 (2) 257-267
    CrossrefPubMedGoogle Scholar
  • 85 Kato K, Kuhara A, Yoneda T , et al. Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response. Mol Cancer Ther 2011; 10 (8) 1430-1439
    CrossrefPubMedGoogle Scholar
  • 86 Gupta PB, Onder TT, Jiang G , et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138 (4) 645-659
    CrossrefPubMedGoogle Scholar
  • 87 Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 2010; 394 (4) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 88 Kim KY, Yu SN, Lee SY , et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun 2011; 413 (1) 80-86
    CrossrefPubMedGoogle Scholar
  • 89 Kim JH, Yoo HI, Kang HS, Ro J, Yoon S. Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem Biophys Res Commun 2012; 418 (1) 98-103
    CrossrefPubMedGoogle Scholar
  • 90 Mitani M, Yamanishi T, Miyazaki Y. Salinomycin: a new monovalent cation ionophore. Biochem Biophys Res Commun 1975; 66 (4) 1231-1236
    CrossrefPubMedGoogle Scholar
  • 91 Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 2009; 390 (3) 743-749
    CrossrefPubMedGoogle Scholar
  • 92 Riccioni R, Dupuis ML, Bernabei M , et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 2010; 45 (1) 86-92
    CrossrefPubMedGoogle Scholar
  • 93 Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH. Salinomycin selectively targets ‘CD133+’ cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol 2011; 18 (6) 1797-1804
    CrossrefPubMedGoogle Scholar
  • 94 Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A 2011; 108 (32) 13253-13257
    CrossrefPubMedGoogle Scholar